Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …

Currently, immune checkpoint blockade (ICB) therapies that target the programmed cell
death ligand-1 (PD-L1) have been used as revolutionary cancer treatments in the clinic …

The response rate of pancreatic cancer to chemotherapy or immunotherapy pancreatic
cancer is low. Although minimally invasive irreversible electroporation (IRE) ablation is a …

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC),
contributing to early metastasis and poor patient survival. Compared to the localized tumors …

The survival of malignant tumors is highly dependent on their intrinsic self-defense pathways
such as heat shock protein (HSP) during cancer therapy. However, precisely dismantling …

Immunotherapy is a new type of tumor treatment after surgery, radiotherapy and
chemotherapy, which can be used to manage and destroy tumor cells through activating or …

Background Cuproptosis, a novel mode of cell death associated with the tricarboxylic acid
(TCA) cycle, is relevant to the development of cancer. However, the impact of single-cell …

Abstract PD-1 (programed death-1)/PD-L1 (programed death-1 ligand) blockade represents
a major breakthrough of anti-cancer therapies, however, it may come with increased risk of …

Malignancy is a serious life-threatening disease, so various therapeutic strategies have
been developed over time. Unfortunately, the treatments currently in use cannot effectively …

This study aimed to assess the therapeutic effect of immune checkpoint inhibitors (ICIs) in
patients with unresectable hepatocellular carcinoma (uHCC) and investigate the correlation …